S. Nyovanie

Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study

M. Mulligan, C. Rapôso, Y. Velmurugu, 2022, Annals of neurology.

Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study

M. Mulligan, R. Pedotti, C. Rapôso, 2022, medRxiv.

Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies

M. Mulligan, C. Rapôso, Y. Velmurugu, 2022, medRxiv.

Molecular mechanism of phosphopeptide neoantigen immunogenicity

M. Findeis, Y. Patskovsky, B. Joshi, 2023, Nature communications.

Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination

Y. Velmurugu, M. Cabatingan, M. Samanovic, 2024, Annals of clinical and translational neurology.